Home › Trials › NCT06647550
Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 19 to 75

Evaluating HD-6277 for Type 2 Diabetes Control

Official title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Run by Hyundai Pharm · NCT06647550 · Data updated 2026-11-12

This study is testing a new medication called HD-6277 to see if it can help adults with Type 2 Diabetes better control their blood sugar when diet and exercise alone aren't enough.

Quick facts

PhasePhase 2
Study typeInterventional
Ages19 Years to 75 Years
SexAll
Enrollment160 (estimated)
SponsorHyundai Pharm
Industry-sponsored
Locations1 site (Seoul)
StatusRecruiting
StartedDecember 12, 2024
Main results expectedMarch 31, 2025
Study endsDecember 31, 2026
Registry record updatedDecember 13, 2024
Trial IDNCT06647550 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults diagnosed with Type 2 Diabetes Mellitus who have an HbA1c level between 7.0% and 10.0% while on diet and exercise alone.

Probably not a fit

Patients with Type 1 diabetes, other immune-mediated diabetes syndromes, or a BMI greater than 40 kg/m2 may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial aims to assess the efficacy and safety of HD-6277 in adults who have inadequate control of Type 2 Diabetes Mellitus through diet and exercise alone. The study is designed as a multi-center, double-blind, randomized, placebo-controlled, parallel-group, dose-finding trial. Participants will receive different doses of HD-6277 or a placebo to determine the optimal dosage for improving diabetes management. The trial will monitor participants' blood sugar levels and overall health throughout the study period.

Why it matters

Potential benefit: If successful, this treatment could provide better control of blood sugar levels for patients with Type 2 Diabetes Mellitus.

How similar studies have gone: Other studies have shown promise in using similar approaches for managing Type 2 Diabetes, but the specific efficacy of HD-6277 is still being evaluated.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening.

Exclusion Criteria:

* Type 1 diabetes or another immune-mediated diabetes syndrome
* BMI: \> 40 kg/m2
* C-peptide: \< 0.5ng/mL

Where it's running

  • Korea University Anam Hospital
    Seoul, South Korea     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 2 Diabetes Mellitus (T2DM) 68
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.